Abstract
Performances of anti-nuclear antibody testing by immunofluorescence assay (ANA-IFA) and enzyme immunoassay (ANA-EIA) were compared in relation to patient diagnosis. A total of 467 patient serum samples were tested by ANA-IFA (Kallestad; Sanofi) and ANA-EIA (RADIAS; Bio-Rad), and their age, sex, diagnosis, disease status, and medications were obtained through chart review. Reference ranges were established by testing 98 healthy blood donor samples. Eighty-six samples came from patients with diffuse connective tissue diseases, including systemic lupus erythematosus, discoid lupus erythematosus, or drug-induced lupus (n = 71); systemic sclerosis, CREST syndrome (calcinosis, Raynaud's phenomenon, esophageal motility abnormalities, sclerodactyly, and telangiectasia), or Raynaud's syndrome (n = 8); Sjögren's syndrome (n = 5); mixed connective tissue disease (n = 5); and polymyositis or dermatomyositis (n = 3). The sensitivity, specificity, positive predictive value, and negative predictive value for ANA-IFA were 87.2, 48.0, 29.1, and 93.9%, respectively, for the reference range of < 1:160. For ANA-EIA, they were 90.7, 60.2, 35.8, and 96.4%, respectively, for the reference range of < 0.9. ANA-EIA offers equivalent sensitivity and higher specificity compared to ANA-IFA.
Full Text
The Full Text of this article is available as a PDF (82.0 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Check W. A. New autoimmune tests seek acceptance. CAP Today. 1995 Apr;9(4):1, 28, 32-4 passim. [PubMed] [Google Scholar]
- Fritzler M. J., Kinsella T. D. The CREST syndrome: a distinct serologic entity with anticentromere antibodies. Am J Med. 1980 Oct;69(4):520–526. doi: 10.1016/0002-9343(80)90462-3. [DOI] [PubMed] [Google Scholar]
- Homburger H. A. Cascade testing for autoantibodies in connective tissue diseases. Mayo Clin Proc. 1995 Feb;70(2):183–184. doi: 10.4065/70.2.183. [DOI] [PubMed] [Google Scholar]
- James K., Meek G. Evaluation of commercial enzyme immunoassays compared to immunofluorescence and double diffusion for autoantibodies associated with autoimmune diseases. Am J Clin Pathol. 1992 Apr;97(4):559–565. doi: 10.1093/ajcp/97.4.559. [DOI] [PubMed] [Google Scholar]
- Jaskowski T. D., Schroder C., Martins T. B., Mouritsen C. L., Litwin C. M., Hill H. R. Screening for antinuclear antibodies by enzyme immunoassay. Am J Clin Pathol. 1996 Apr;105(4):468–473. doi: 10.1093/ajcp/105.4.468. [DOI] [PubMed] [Google Scholar]
- Moncé N. M., Jr, Bogusky R. T., Cappel N. N. An enzyme immunoassay screening test for the detection of total antinuclear antibodies. J Clin Lab Anal. 1991;5(6):439–442. doi: 10.1002/jcla.1860050612. [DOI] [PubMed] [Google Scholar]
- Moroi Y., Peebles C., Fritzler M. J., Steigerwald J., Tan E. M. Autoantibody to centromere (kinetochore) in scleroderma sera. Proc Natl Acad Sci U S A. 1980 Mar;77(3):1627–1631. doi: 10.1073/pnas.77.3.1627. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Swaak A. J., Huysen V., Smeenk R. J. Antinuclear antibodies in routine analysis: the relevance of putative clinical associations. Ann Rheum Dis. 1993 Feb;52(2):110–114. doi: 10.1136/ard.52.2.110. [DOI] [PMC free article] [PubMed] [Google Scholar]
- White R. H., Robbins D. L. Clinical significance and interpretation of antinuclear antibodies. West J Med. 1987 Aug;147(2):210–213. [PMC free article] [PubMed] [Google Scholar]
- Xavier R. M., Yamauchi Y., Nakamura M., Tanigawa Y., Ishikura H., Tsunematsu T., Kobayashi S. Antinuclear antibodies in healthy aging people: a prospective study. Mech Ageing Dev. 1995 Mar 1;78(2):145–154. doi: 10.1016/0047-6374(94)01532-q. [DOI] [PubMed] [Google Scholar]
- Zweig M. H., Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem. 1993 Apr;39(4):561–577. [PubMed] [Google Scholar]